- ‘Clear Advantage’ of GLP-1s for IIH vs Conventional Therapy
Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery
- FDA Drug and Device Approvals: May 20, 2004 - Medscape
May 20, 2004 — The U S Food and Drug Administration (FDA) has approved moxifloxacin for community-acquired pneumonia, docetaxel for prostate cancer, morphine sulfate extended-release liposome
- Spice-Med Interactions: What Every Clinician Needs to Know
Cinnamon, turmeric, and ginger may interact with anticoagulants and chemotherapeutics, raising bleeding risk and reducing drug efficacy in high doses
- New Oral Weight Loss Drugs: Where Are We and Whats Next?
Several promising drugs in phase 2 testing and beyond seek to offer patients a more convenient alternative to already popular injectable formulations
- Conference MDAngle: ASCO 2025 Prostate Cancer - Medscape
Insights from ASCO 2025, including anticipated presentations, key takeaways, and how new research in prostate cancer may impact patients
- Alternative Funders and Costly Meds: Are Patients Insured?
“Alternative funders” in employer self-funded health plans can leave patients uninsured for costly meds — read a patient’s real story of confusion, financial risk, and an advocate’s
- Real-World Data: Adjuvant Therapy for BRAF-Mutated Melanoma
Dr Teresa Amaral finishes the discussion about real-world data on adjuvant therapy in patients with BRAF-mutated melanoma
- No Bad Foods: All Foods Exist in a Gray Area - Medscape
Staple foods such as flour and salt have been labeled as bad, but that’s not necessarily the case Not consuming those staples means people aren’t getting the enhancements added to these foods
|